In the past 2 years, substantial improvements have been made in the management of advanced-stage EGFR-mutant non-small-cell lung cancer. Recent studies have suggested added benefit from the combination of third-generation tyrosine-kinase inhibitors with either chemotherapy or a bispecific antibody targeting EGFR and MET. Herein, we summarize these advances and their implications for clinical practice.

中文翻译：

---

MARIPOSA 试验 — 对 EGFR 突变型 NSCLC 治疗的影响


在过去的 2 年中，晚期 EGFR 突变非小细胞肺癌的管理取得了实质性进展。最近的研究表明，第三代酪氨酸激酶抑制剂与化疗或靶向 EGFR 和 MET 的双特异性抗体联合使用可带来更多益处。在本文中，我们总结了这些进展及其对临床实践的影响。